153 related articles for article (PubMed ID: 32193219)
1. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin.
Lin LL; Lakomy DS; Ning MS; Simpkins F; Jhingran A
Int J Gynecol Cancer; 2020 Apr; 30(4):409-423. PubMed ID: 32193219
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L; Matulonis U
Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
[TBL] [Abstract][Full Text] [Related]
3. [3rd National Congress of Medical Oncology. Issues in Gynecologic Oncology. Naples, November 7, 2000].
Longo F; Mansueto G
Tumori; 2001; 87(6):A15-21. PubMed ID: 11995698
[No Abstract] [Full Text] [Related]
4. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
6. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
7. [Trends in comprehensive treatment for gynecologic malignancies].
Yakushiji M; Fujiyoshi K; Komai K; Imamura K
Gan To Kagaku Ryoho; 1999 Jun; 26 Suppl 1():145-56. PubMed ID: 10410669
[TBL] [Abstract][Full Text] [Related]
8. Issues in gynecologic radiation oncology.
Randall ME; Evans L
Curr Opin Oncol; 1991 Oct; 3(5):920-9. PubMed ID: 1751583
[TBL] [Abstract][Full Text] [Related]
9. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
Front Immunol; 2018; 9():3107. PubMed ID: 30692993
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. A Gynecologic Oncology Group Study.
Manetta A; Boyle J; Berman ML; DiSaia PJ; Lentz S; Liao SY; Mutch D; Slater L
Cancer; 1994 Jan; 73(1):196-9. PubMed ID: 8275425
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer: Molecular markers and management of advanced stage disease.
Arend RC; Jones BA; Martinez A; Goodfellow P
Gynecol Oncol; 2018 Sep; 150(3):569-580. PubMed ID: 29843906
[TBL] [Abstract][Full Text] [Related]
12. Treatment of gynecological malignancies with a combination of cisplatin, adriamycin and ifosfamide.
Nishida T; Nagasue N; Yakushiji M
Cancer Chemother Pharmacol; 1990; 26 Suppl():S39-42. PubMed ID: 2347048
[TBL] [Abstract][Full Text] [Related]
13. International Clinical Trials in Radiation Oncology. Gynecology: combined radiotherapy and chemotherapy in gynecologic oncology.
Brady LW; Markoe AM; DeEulis T; Lewis GC
Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S203-9. PubMed ID: 3292477
[No Abstract] [Full Text] [Related]
14. Towards prediction and modulation of treatment response.
Bartelink H; Begg A; Martin JC; van Dijk M; van 't Veer L; van der Vaart P; Verheij M
Radiother Oncol; 1999 Jan; 50(1):1-11. PubMed ID: 10225551
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers.
Ferriss JS; Williams-Brown MY
Curr Treat Options Oncol; 2019 Aug; 20(10):75. PubMed ID: 31444655
[TBL] [Abstract][Full Text] [Related]
16. The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: preliminary results.
Varlotto JM; Gerszten K; Heron DE; Comerci J; Gautam S; Selvaraj R; Lalonde R; Chura JC
Am J Clin Oncol; 2006 Jun; 29(3):281-9. PubMed ID: 16755182
[TBL] [Abstract][Full Text] [Related]
17. The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix.
Thigpen T; Vance R; Khansur T; Malamud F
Semin Oncol; 1996 Jun; 23(3 Suppl 6):56-64. PubMed ID: 8677451
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase I/II studies of definitive irradiation and chemotherapy for advanced gynecologic malignancies.
Grigsby PW; Graham MV; Perez CA; Galakatos AE; Camel HM; Kao MS
Am J Clin Oncol; 1996 Feb; 19(1):1-6. PubMed ID: 8554027
[TBL] [Abstract][Full Text] [Related]
19. [Current status and future direction of definitive chemoradiotherapy for esophageal cancer].
Ito Y
Nihon Shokakibyo Gakkai Zasshi; 2014 Feb; 111(2):260-8. PubMed ID: 24500315
[No Abstract] [Full Text] [Related]
20. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
